Imatinib inhibits not only BCR-ABL, the putative cause of CML, but also other tyrosine kinases, such as c-ABL, c-KIT, platelet-derived growth factor receptor (PDGFR), and ARG [18]. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.